These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15963058)

  • 1. Short-term testosterone supplementation does not activate GH and IGF-I production in postmenopausal women.
    Soares-Welch C; Mielke KL; Bowers CY; Veldhuis JD
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):32-8. PubMed ID: 15963058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
    Gentili A; Mulligan T; Godschalk M; Clore J; Patrie J; Iranmanesh A; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.
    Veldhuis JD; Evans WS; Bowers CY
    J Clin Endocrinol Metab; 2002 Feb; 87(2):859-66. PubMed ID: 11836333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol potentiates ghrelin-stimulated pulsatile growth hormone secretion in postmenopausal women.
    Veldhuis JD; Keenan DM; Iranmanesh A; Mielke K; Miles JM; Bowers CY
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3559-65. PubMed ID: 16804038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.
    Anderson SM; Shah N; Evans WS; Patrie JT; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):551-60. PubMed ID: 11158008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
    Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism.
    Veldhuis JD; Keenan DM; Bailey JN; Miles JM; Bowers CY
    Eur J Endocrinol; 2009 Aug; 161(2):293-300. PubMed ID: 19458139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.
    Veldhuis JD; Bowers CY
    Am J Physiol Endocrinol Metab; 2009 May; 296(5):E1085-92. PubMed ID: 19240251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations.
    Veldhuis JD; Anderson SM; Iranmanesh A; Bowers CY
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1613-7. PubMed ID: 15585557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy.
    Veldhuis JD; Keenan DM; Mielke K; Miles JM; Bowers CY
    Eur J Endocrinol; 2005 Oct; 153(4):577-86. PubMed ID: 16189179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term estradiol replacement in postmenopausal women selectively mutes somatostatin's dose-dependent inhibition of fasting growth hormone secretion.
    Bray MJ; Vick TM; Shah N; Anderson SM; Rice LW; Iranmanesh A; Evans WS; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3143-9. PubMed ID: 11443179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.
    Anderson SM; Wideman L; Patrie JT; Weltman A; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5904-11. PubMed ID: 11739462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estradiol supplementation enhances submaximal feed-forward drive of growth hormone (GH) secretion by recombinant human GH-releasing hormone-1,44-amide in a putatively somatostatin-withdrawn milieu.
    Veldhuis JD; Evans WS; Bowers CY
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5484-9. PubMed ID: 14602794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.